Ai Driven Rare Disease Drug Discovery Market
AI-Driven Rare-Disease Drug-Discovery Market Forecasts to 2032 – Global Analysis By Drug Type (Small Molecule Drugs, Biologics, Gene Therapies and RNA-Based Therapeutics), Indication, Technology, Application, End User, and By Geography.
According to Stratistics MRC, the Global AI-Driven Rare-Disease Drug-Discovery Market is accounted for $5.9 billion in 2025 and is expected to reach $37.7 billion by 2032 growing at a CAGR of 30.1% during the forecast period. AI-Driven Rare-Disease Drug Discovery uses machine learning to identify therapeutic targets, predict compound efficacy, and accelerate clinical trial design for rare and orphan diseases. By analyzing genomic, proteomic, and patient data, AI models uncover hidden patterns and repurpose existing drugs. This approach reduces R&D costs and timelines while improving success rates. Biotech firms and research institutions leverage these tools to address unmet medical needs, especially in conditions with limited commercial incentives, transforming how niche therapeutics are developed.
According to the National Institutes of Health, AI models trained on multi-omics data are now capable of identifying novel drug targets for rare genetic disorders that were previously considered "undruggable" due to a lack of understanding of their underlying pathology.
Market Dynamics:
Driver:
Advancements in machine learning algorithms
Rapid progress in machine learning is revolutionizing rare-disease drug discovery by enabling faster, more accurate target identification and compound screening. AI models can analyze complex genomic, proteomic, and clinical datasets to uncover novel therapeutic pathways. These algorithms reduce R&D timelines and improve success rates in early-stage drug development. As computational biology and deep learning techniques mature, pharmaceutical companies are increasingly integrating AI to address rare diseases with limited treatment options, driving innovation and expanding the scope of precision medicine.
Restraint:
Limited availability of patient datasets
Rare diseases inherently suffer from small patient populations, resulting in limited clinical and genomic datasets. This data scarcity hampers AI model training, validation, and generalizability. Incomplete or fragmented records reduce algorithmic accuracy and slow drug development. Privacy regulations and data silos further restrict access to high-quality datasets. Overcoming this restraint requires global data-sharing initiatives, synthetic data generation, and partnerships with patient advocacy groups. Without expanded data availability, AI’s full potential in rare-disease drug discovery remains constrained.
Opportunity:
Collaborations between AI firms and pharma
Strategic partnerships between AI technology providers and pharmaceutical companies are unlocking new opportunities in rare-disease drug discovery. These collaborations combine computational expertise with clinical and regulatory know-how, accelerating pipeline development. Joint ventures enable shared access to proprietary datasets, compound libraries, and disease models. As pharma seeks to de-risk R&D and improve ROI, AI firms offer scalable platforms for target prediction, molecule design, and trial optimization. Such alliances are reshaping drug discovery workflows and expanding therapeutic possibilities.
Threat:
Ethical and data privacy concerns
AI-driven drug discovery raises ethical and privacy concerns, especially in rare diseases where patient data is highly identifiable. Misuse of sensitive health information, lack of informed consent, and opaque algorithmic decisions can erode trust. Regulatory scrutiny around data governance, bias mitigation, and explainability is intensifying. Companies must implement robust data protection protocols, transparent AI models, and ethical review frameworks. Failure to address these risks may lead to reputational damage, legal challenges, and reduced stakeholder confidence.
Covid-19 Impact:
The COVID-19 pandemic accelerated adoption of AI in drug discovery, including rare diseases. Disruptions in clinical trials and lab access prompted a shift toward in silico modeling and virtual screening. AI platforms enabled remote collaboration, rapid hypothesis testing, and repurposing of existing compounds. The crisis highlighted the need for agile, data-driven R&D approaches. Post-pandemic, AI continues to play a central role in rebuilding resilient drug pipelines, with increased investment and regulatory support for digital innovation in rare-disease research.
The small molecule drugs segment is expected to be the largest during the forecast period
The small molecule drugs segment is expected to account for the largest market share during the forecast period, due to its established development pathways, scalability, and compatibility with AI-driven screening. These compounds are easier to synthesize, modify, and test using computational models. AI accelerates lead identification, toxicity prediction, and optimization of pharmacokinetics. Small molecules remain the preferred modality for targeting intracellular pathways and rare genetic mutations. Their cost-effectiveness and regulatory familiarity further support widespread adoption in AI-assisted rare-disease drug development.
The rare cancers segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the rare cancers segment is predicted to witness the highest growth rate, driven by unmet clinical needs and growing genomic data availability. AI tools are increasingly used to identify biomarkers, stratify patients, and design targeted therapies for rare oncology indications. Advances in multi-omics integration and real-world evidence analysis enhance treatment personalization. As precision oncology expands, rare cancer research benefits from AI’s ability to uncover actionable insights from limited datasets. This segment’s urgency and innovation potential fuel rapid growth.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by rising healthcare investments, expanding biotech ecosystems, and government-led AI initiatives. Countries like China, Japan, and South Korea are integrating AI into national drug discovery programs and rare-disease registries. Regional pharma companies are partnering with AI startups to accelerate pipeline development. The region’s large population base and increasing rare-disease diagnosis rates further drive demand. Asia Pacific’s proactive stance on digital health positions it as a market leader.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR due to its advanced AI infrastructure, strong pharmaceutical presence, and supportive regulatory environment. The U.S. leads in AI-driven drug discovery through academic research, venture capital funding, and FDA pilot programs. Rare-disease advocacy groups and data-sharing networks enhance clinical trial recruitment and model training. Collaborations between tech giants and pharma firms are accelerating innovation. As precision medicine and orphan drug development gain momentum, North America drives rapid market expansion.
Key players in the market
Some of the key players in AI-Driven Rare-Disease Drug-Discovery Market include NVIDIA, Insilico Medicine, Exscientia, BenevolentAI, Google, Recursion Pharmaceuticals, Atomwise, Sanofi, Roche, Moderna, Genentech, Pfizer, IBM, AstraZeneca, CytoReason, BioNTech, Takeda and Novartis.
Key Developments:
In October 2025, Insilico Medicine announced the first AI-discovered novel target for a rare fibrosis disease has entered Phase I trials, potentially cutting years from the traditional discovery timeline.
In September 2025, NVIDIA and Recursion Pharmaceuticals expanded their collaboration, launching a new AI supercomputer platform to map the cellular biology of hundreds of poorly understood rare genetic disorders.
In August 2025, a consortium led by AstraZeneca and BenevolentAI initiated a $250 million project to apply their AI knowledge graphs to de-risk and accelerate the development of rare neurological disease therapies.
Drug Types Covered:
• Small Molecule Drugs
• Biologics
• Gene Therapies
• RNA-Based Therapeutics
Indications Covered:
• Neuromuscular Disorders
• Rare Cancers
• Metabolic Disorders
• Genetic Syndromes
• Immunological Disorders
Technologies Covered:
• Machine Learning
• Deep Learning
• NLP & Bioinformatics
• Computational Chemistry
• Knowledge Graph Modeling
Applications Covered:
• Target Identification
• Drug Repurposing
• Clinical Trial Optimization
• Biomarker Discovery
End Users Covered:
• Pharmaceutical Companies
• Biotechnology Startups
• Research Institutions
• Contract Research Organizations
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global AI-Driven Rare-Disease Drug-Discovery Market, By Drug Type
5.1 Introduction
5.2 Small Molecule Drugs
5.3 Biologics
5.4 Gene Therapies
5.5 RNA-Based Therapeutics
6 Global AI-Driven Rare-Disease Drug-Discovery Market, By Indication
6.1 Introduction
6.2 Neuromuscular Disorders
6.3 Rare Cancers
6.4 Metabolic Disorders
6.5 Genetic Syndromes
6.6 Immunological Disorders
7 Global AI-Driven Rare-Disease Drug-Discovery Market, By Technology
7.1 Introduction
7.2 Machine Learning
7.3 Deep Learning
7.4 NLP & Bioinformatics
7.5 Computational Chemistry
7.6 Knowledge Graph Modeling
8 Global AI-Driven Rare-Disease Drug-Discovery Market, By Application
8.1 Introduction
8.2 Target Identification
8.3 Drug Repurposing
8.4 Clinical Trial Optimization
8.5 Biomarker Discovery
9 Global AI-Driven Rare-Disease Drug-Discovery Market, By End User
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Biotechnology Startups
9.4 Research Institutions
9.5 Contract Research Organizations
10 Global AI-Driven Rare-Disease Drug-Discovery Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 NVIDIA
12.2 Insilico Medicine
12.3 Exscientia
12.4 BenevolentAI
12.5 Google
12.6 Recursion Pharmaceuticals
12.7 Atomwise
12.8 Sanofi
12.9 Roche
12.10 Moderna
12.11 Genentech
12.12 Pfizer
12.13 IBM
12.14 AstraZeneca
12.15 CytoReason
12.16 BioNTech
12.17 Takeda
12.18 Novartis
List of Tables
1 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Region (2024-2032) ($MN)
2 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Drug Type (2024-2032) ($MN)
3 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
4 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Biologics (2024-2032) ($MN)
5 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Gene Therapies (2024-2032) ($MN)
6 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By RNA-Based Therapeutics (2024-2032) ($MN)
7 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Indication (2024-2032) ($MN)
8 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Neuromuscular Disorders (2024-2032) ($MN)
9 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Rare Cancers (2024-2032) ($MN)
10 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
11 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Genetic Syndromes (2024-2032) ($MN)
12 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Immunological Disorders (2024-2032) ($MN)
13 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Technology (2024-2032) ($MN)
14 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Machine Learning (2024-2032) ($MN)
15 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Deep Learning (2024-2032) ($MN)
16 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By NLP & Bioinformatics (2024-2032) ($MN)
17 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Computational Chemistry (2024-2032) ($MN)
18 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Knowledge Graph Modeling (2024-2032) ($MN)
19 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Application (2024-2032) ($MN)
20 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Target Identification (2024-2032) ($MN)
21 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Drug Repurposing (2024-2032) ($MN)
22 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Clinical Trial Optimization (2024-2032) ($MN)
23 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
24 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By End User (2024-2032) ($MN)
25 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
26 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Biotechnology Startups (2024-2032) ($MN)
27 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Research Institutions (2024-2032) ($MN)
28 Global AI-Driven Rare-Disease Drug-Discovery Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
